Αρχική World News A Third Of Breast Cancer Survivors Have Vaginal Atrophy, But Most Are...

A Third Of Breast Cancer Survivors Have Vaginal Atrophy, But Most Are Too Embarrassed To Get Help

Vulvovaginal atrophy (atrophic vaginitis) affects roughly a third of breast cancer survivors and negatively impacts their quality of life in multiple ways.The condition can lead to thinning, drying, and inflammation of the vaginal walls and typically occurs when the body produces less estrogen than normal. It can make daily life and activities uncomfortable, and can make also make sex painful. Vulvovaginal atrophy (VVA) affects about half of all postmenopausal women.Research has shown that it is a significantly underreported condition.“It’s not just a minor lifestyle problem,” said Holly L. Thacker, MD, Professor and Director of Cleveland Clinic Center for Specialized Women’s Health. “There’s a lot of significant known risk of untreated atrophy: bleeding, pain, sexual dysfunction, destroyed relationships, recurrent bladder infections that can even lead to urosepsis.”Photo: Adobe Stock/ruigsantos
Additional terms that are sometimes used to describe symptoms associated with VVA include vaginal atrophy, atrophic vaginitis, urogenital atrophy, or genitourinary syndrome of menopause (GSM). All are caused by low estrogen levels in vulvovaginal tissue.According to the National Center for Biotechnology Information, only about 7% of women affected seek treatment when they first notice the symptoms, and 25% of women with the condition said it had a negative effect on other areas of their life, like sleep, sexual health, and general happiness.A long life expectancy paired with the onset of the condition around menopause means some women are spending more than a third of their lives with VVA.There are available treatments to ease symptoms, yet many women don’t seek them out. This could be due to the patient’s embarrassment or reluctance to talk about her vagina with her doctor, and/or the hesitancy of healthcare professionals to broach such a sensitive topic during routine visits.Photo: Adobe Stock/Andrey Kuzmin
Recent research on vulvovaginal atrophy in breast cancer survivors was led by a Delphi Panel and published in the journal Supportive Care in Cancer.Delphi Panel methodology relies on a panel of experts (including academics and doctors) who follow a structured, scientific process of collecting and analyzing information about a problem when there is a lack of complete and definitive evidence. They send out open-ended surveys, analyze feedback, and send out additional surveys for reassessment until each expert has created a comprehensive summary of the issue.For this study, an Italian Delphi Panel analyzed risk factors for vulvovaginal atrophy, its coexisting conditions, current treatments, areas of care that can be improved, and more.Photo: Adobe Stock/olgasparrow
The panel researched the issue, emailed a questionnaire to participants in Italy, engaged in a 1-day panel, sent out two more rounds of follow-up interviews, and then completed their analysis. The entire process took about two years.They found that VVA affects about 30% of breast cancer survivors (115,000 cases out of 380,000). They also found that depression and other psychological issues were common in VVA patients, and more severe in patients who had a history of breast cancer.In order to meet the needs of breast cancer patients with VVA, the panel estimated that more doctor visits need to be made. Specifically, they recommend there needs to be 33.4 additional gynecological visits a year for every 100 current visits, 22.8 additional cancer screenings, 7.07 additional outpatient visits, and 5.04 screenings for human papillomavirus.Photo: Adobe Stock/rocketclips
Simple and effective treatments are readily available, including non-hormonal treatments like vaginal gels, moisturizers, and lubricants.In particular, a non-hormonal, oral pill called Ospemifene can be used to treat VVA in women with a history of breast cancer. Vaginal laser was also seen to be helpful in treating VVA in breast cancer survivors, but there is not enough evidence to conclude how helpful it is in the long term.According to the Mayo Clinic, regular sexual activity (with or without a partner) could help prevent symptoms of VVA because sexual activity increases blood flow to the vagina, which, in turn, helps keep vaginal tissues healthy.Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

ESMO 2020: New Treatments for Advanced Kidney Cancer, Prostate Cancer, and Bladder Cancer

The 2020 European Society for Medical Oncology (ESMO) Virtual Congress was held online from September 19 to September 21. In this podcast, Neeraj Agarwal,...

The UK Government’s spending review: Time to invest in the future of cancer care

This autumn, the chancellor Rishi Sunak will go to Parliament and set out the UK Government’s spending priorities in the Comprehensive Spending Review...

FDA Extends Approval of Pembrolizumab for Classical Hodgkin Lymphoma

On 14 October 2020, the US Food and Drug Administration (FDA) extended the approval of pembrolizumab (KEYTRUDA®, Merck Sharp & Dohme Corp.) for the...

31-Year-Old Mother Dies of Cancer After Her Chemotherapy Was Paused During the Pandemic

The COVID-19 pandemic has been a scary and difficult thing for most of the world, and it’s important to keep safety protocols in place...

For Esophageal Cancer, Immunotherapy Likely to Play Larger Role

October 19, 2020, by NCI Staff An esophagram using barium contrast shows the esophagus. Credit: iStock Immunotherapy may become part of early treatment for some people with...

Targeted Therapy Based on Molecular Profiling of Malignant Mesothelioma Tumours Is Feasible

Targeted therapy recommendations can be made based on the molecular profiles of tumour samples from patients with metastatic malignant mesothelioma (MM) according to findings...